The effect and mechanism of tamoxifen-induced hepatocyte steatosis in Vitro

International Journal of Molecular Sciences

Volumn 15, Issue 3, 2014, Pages 4019-4030

  Zhao, Fei ^a   Xie, Ping ^b   Jiang, Jiali ^a   Zhang, Lingqiang ^b   An, Wei ^c   Zhan, Yutao ^a  

^a CAPITAL MEDICAL UNIVERSITY   (China)

^b BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^c CAPITAL MEDICAL UNIVERSITY   (China)

Author keywords

HepG 2 Cells; Non alcoholic fatty liver disease; Tamoxifen; Triglyceride

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; ACYL COENZYME A DESATURASE; CARNITINE PALMITOYLTRANSFERASE I; CCAAT ENHANCER BINDING PROTEIN ALPHA; CHOLECYSTOKININ OCTAPEPTIDE; FATTY ACID SYNTHASE; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; TAMOXIFEN; TRIACYLGLYCEROL; ANTIESTROGEN; FATTY ACID; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ARTICLE; CELL PROLIFERATION; CELL VIABILITY; CONTROLLED STUDY; FATTY ACID SYNTHESIS; FATTY LIVER; GENE CONTROL; GENE EXPRESSION; HUMAN; HUMAN CELL; LIPID METABOLISM; LIPID STORAGE; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION; WESTERN BLOTTING; BIOSYNTHESIS; CELL SURVIVAL; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; HEPG2 CELL LINE; LIVER CELL; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; PATHOLOGY; TOXICITY;

ACETYL-COA CARBOXYLASE; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL PROLIFERATION; CELL SURVIVAL; ESTROGEN ANTAGONISTS; FATTY ACID SYNTHASES; FATTY ACIDS; FATTY LIVER; GENE EXPRESSION; HEP G2 CELLS; HEPATOCYTES; HUMANS; LIPID METABOLISM; LIVER NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; STEAROYL-COA DESATURASE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TAMOXIFEN; TRIGLYCERIDES;

EID: 84896473042     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms15034019     Document Type: Article

References (30)

1. Boyle, P. Triple-negative breast cancer: Epidemiological considerations and recommendations. Ann. Oncol. 2012, 23, vi7-vi12.
2. Zeng, Z. J.; Li, J. H.; Zhang, Y. J.; Zhao, S. T. Optimal combination of radiotherapy and endocrine drugs in breast cancer treatment. Cancer Radiother. 2013, 17, 208-214.
3. Afonso, N. Women at high risk for breast cancer-What the primary care provider needs to know. J. Am. Board Fam. Med. 2009, 22, 43-50.
4. Colozza, M.; Califano, R.; Minenza, E.; Dinh, P.; Azambuja, E. Aromatase inhibitors: A new reality for the adjuvant endocrine treatment of early-stage breast cancer in postmenopausal women. Mini Rev. Med. Chem. 2008, 8, 564-574.
5. Tomao, F.; Spinelli, G.; Vici, P.; Pisanelli, G. C.; Cascialli, G.; Frati, L.; Panici, P. B.; Tomao, S. Current role and safety profile of aromatase inhibitors in early breast cancer. Expert Rev. Anticancer Ther. 2011, 11, 1253-1263.
6. Lee, M. H.; Kim, J. W.; Kim, J. H.; Kang, K. S.; Kong, G.; Lee, M. O. Gene expression profiling of murine hepatic steatosis induced by tamoxifen. Toxicol. Lett. 2010, 199, 416-424.
7. Cole, L. K.; Jacobs, R. L.; Vance, D. E. Tamoxifen induces triacylglycerol accumulation in the mouse liver by activation of fatty acid synthesis. Hepatology 2010, 52, 1258-1265.
8. Gómez-Lechón, M. J.; Donato, M. T.; Castell, J. V.; Jover, R. Human hepatocytes as a tool for studying toxicity and drug metabolism. Curr. Drug Metab. 2003, 4, 292-312.
9. Gómez-Lechón, M. J.; Donato, M. T.; Castell, J. V.; Jover, R. Human hepatocytes in primary culture: The choice to investigate drug metabolism in man. Curr. Drug Metab. 2004, 5, 443-462.
10. Gómez-Lechón, M. J.; Donato, M. T.; Martínez-Romero, A.; Jiménez, N.; Castell, J. V.; O'Connor, J. E. A human hepatocellular in vitro model to investigate steatosis. Chem. Biol. Interact. 2007, 165, 106-116.
11. Nishino, M.; Hayakawa, K.; Nakamura, Y.; Morimoto, T.; Mukaihara S. Effects of tamoxifen on hepatic fat content and the development of hepatic steatosis in patients with breast cancer: High frequency of involve-ment and rapid reversal after completion of tamoxifen therapy. AJR Am. J. Roentgenol. 2003, 180, 129-134.
12. Murata, Y.; Ogawa, Y.; Saibara, T.; Nishioka, A.; Fujiwara, Y.; Fukumoto, M.; Inomata, T.; Enzan, H.; Onishi, S.; Yoshida, S. Unrecognized hepatic steatosis and non-alcoholic steatohepatitis in adjuvant tamoxifen for breast cancer patients. Oncol. Rep. 2000, 7, 1299-1304.
13. Bruno, S.; Maisonneuve, P.; Castellana, P.; Rotmensz, N.; Rossi, S.; Maggioni, M.; Persico, M.; Colombo, A.; Monasterolo, F.; Casadei-Giunchi, D.; et al. Incidence and risk factors for non-alcoholic steatohepatitis: Prospective study of 5408 women enrolled in Italian tamoxifen chemo-prevention trial. BMJ 2005, 330, 932.
14. Akhondi-Meybodi, M.; Mortazavy-Zadah, M. R.; Hashemian, Z.; Moaiedi, M. Incidence and risk factors for non-alcoholic steatohepatitis in females treated with tamoxifen for breast cancer. Arab. J. Gastroenterol. 2011, 12, 34-36.
15. Lelliott, C. J.; López, M.; Curtis, R. K.; Parker, N.; Laudes, M.; Yeo, G.; Jimenez-Liñan, M.; Grosse, J.; Saha, A. K.; Wiggins, D.; et al. Transcirpt and metabolite analysis of the effects of tamoxifen in rat liver reveals inhibition of fatty acid synthesis in the presence of hepatic steatosis. FASEB J. 2005, 19, 1108-1119.
16. Donnelly, K. L.; Smith, C. I.; Schwarzenberg S. J.; Jessurun J.; Boldt, M. D.; Parks E. J. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Investig. 2005, 115, 1343-1351.
17. Brown, M. S.; Goldstein J. L. The SREBP pathway: Regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997, 89, 331-340.
18. Pettinelli, P.; Obregón, A. M.; Videla, L. A. Molecular mechanisms of steatosis in nonalcoholic fatty liver disease. Nutr. Hosp. 2011, 26, 441-450.
19. Horton, J. D.; Goldstein, J. L.; Brown, M. S. SREBPs: Activators of the complete program of cholesterol and fatty acid synthesis in the liver. J. Clin. Investig. 2002, 109, 1125-1131.
20. Horton, J. D.; Shah, N. A.; Warringto, J. A.; Anderson, N. N.; Park, S. W.; Brown, M. S.; Goldstein, J. L. Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc. Natl. Acad. Sci. USA 2003, 100, 12027-12032.
21. Chow, J. D.; Jones, M. E.; Prelle, K.; Simpson, E. R.; Boon, W. C. As elective estrogen receptor an agonist ameliorates hepatic steatosis in the male aromatase knockout mouse. J. Endocrinol. 2011, 210, 323-334.
22. Strable, M. S.; Ntambi, J. M. Genetic control of de novo lipogenesis: Role in diet-induced obesity. Crit. Rev. Biochem. Mol. Biol. 2010, 45, 199-214.
23. Gudbrandsen, O. A.; Rost, T. H.; Berge, R. K. Causes and prevention of tamoxifen-induced accumulation of triacylglycerol in rat liver. J. Lipid Res. 2006, 47, 2223-2232.
24. Kwak, D. H.; Lee, J. H.; Kim, D. G.; Kim, T.; Lee, K. J.; Ma, J. Y. Inhibitory effects of Hwangryunhaedok-Tang in 3T3-L1 adipogenesis by regulation of Raf/MEK1/ERK1/2 pathway and PDK1/Akt Phosphorylation. Evid. Based Complement. Alternat. Med. 2013, 2013, 413906.
25. Higashi, Y.; Itabe, H.; Fukase, H.; Mori, M.; Fujimoto, Y.; Takano, T. Transmembrane lipid transfer is crucial for providing neutral lipids during very low densitylipoprotein assembly in endoplasmic reticulum. J. Biol. Chem. 2003, 278, 21450-21458.
26. Liang, J. S.; Kim, T.; Fang, S.; Yamaguchi, J.; Weissman, A. M.; Fisher, E. A.; Ginsberg, H. N. Overexpression of the tumor autocrine motility factor receptor Gp78, a ubiquitin protein ligase, results in increased ubiquitinylation and decreased secretion of apolipoprotein B100 in HepG2 cells. J. Biol. Chem. 2003, 278, 23984-23988.
27. Jamil, H.; Dickson, J. K., Jr.; Chu, C. H.; Lago, M. W.; Rinehart, J. K.; Biller, S. A.; Gregg, R. E.; Wetterau J. R. Microsomal triglyceride transfer protein. Specificity of lipid binding and transport. J. Biol. Chem. 1995, 270, 6549-6554.
28. Nakamura, S.; Takamura, T.; Matsuzawa-Nagata, N.; Takayama, H.; Misu, H.; Noda, H.; Nabemoto, S.; Kurita, S.; Ota T.; Ando, H.; et al. Palmitate induces insulin resistance in H4IIEC3 hepatocytes through reactive oxygen species produced by mitochondria. J. Biol. Chem. 2009, 284, 14809-14818.
29. Serviddio, G.; Giudetti, A. M.; Bellanti, F.; Priore, P.; Rollo, T.; Tamborra, R.; Siculella, L.; Vendemiale, G.; Altomare, E.; Gnoni, G. V. Oxidation of hepatic carnitine palmitoyl transferase-I (CPT-I) impairs fatty acid beta-oxidation in rats fed a methionine-choline deficient diet. PLoS One 2011, 6, e24084.
30. Date, S.; Mizuno, H.; Tsuyama, N.; Harada, T.; Masujima, T. Direct drug metabolism monitoring in a live single hepatic cell by video mass spectrometry. Anal. Sci. 2012, 28, 201-203.